Quantcast

Latest TNF inhibitor Stories

2014-07-28 12:57:00

Emory University An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson’s disease, researchers at Emory University School of Medicine have shown. The results were published Thursday, July 24 in the Journal of Parkinson’s Disease. The findings demonstrate that the drug, called XPro1595, can reach the brain at sufficient levels and have beneficial effects when administered by subcutaneous injection, like an...

2014-07-03 08:23:24

- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia(®) (certolizumab pegol) in dermatology. This collaboration aims...

2014-06-19 09:35:10

The JAMA Network Journals In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA. Tumor necrosis factor α (TNF-α)...

2014-06-11 04:21:56

- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were...

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-14 12:31:58

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-14 08:28:16

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_5eu_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-05 08:30:08

- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia(®) (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. Remission was also assessed over the trial period. Results were presented at Digestive Disease Week (DDW), taking place in Chicago from May 3-6. "The...

2014-04-21 12:27:26

Mucosal Healing and Maintenance of Remission Have High Influence in Gastroenterologists' Prescribing Decision for UC, According to Findings from Decision Resources Group BURLINGTON, Mass., April 21, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 gastroenterologists, effect on mucosal healing and improvement in the maintenance of remission are two of the attributes that most strongly influence their prescribing decisions in moderate to severe...

2014-04-09 08:29:57

DUBLIN, April 9, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/stldww/global_psoriasis) has announced the addition of the "Global Psoriasis Therapeutics Market" [http://www.researchandmarkets.com/research/stldww/global_psoriasis ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related